From L-R: Luigi Naldini, Genenta CEO Pierluigi Paracchi and Genenta CMO Carlo Russo
Italian cancer gene therapy biotech makes history with modest Nasdaq IPO
After years of developing its gene therapy for cancer on the outskirts of biotech, Genenta has landed on Nasdaq as the first Italian biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
